Published in Immunol Today on October 01, 1993
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 2.41
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer (1997) 1.61
Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med (1998) 1.60
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer (2009) 1.35
Analysis of HLA-E expression in human tumors. Immunogenetics (2003) 1.23
The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol (1999) 1.21
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer (1995) 1.13
The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol (2016) 1.11
Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol (1995) 1.05
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics (2010) 1.03
Clinical implication of HLA class I expression in breast cancer. BMC Cancer (2011) 0.99
Dendritic cell density and activation status in human breast cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer (2002) 0.97
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer (2004) 0.94
An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer (1997) 0.93
Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin Exp Immunol (1999) 0.92
Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci U S A (1997) 0.91
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology (2012) 0.91
Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2014) 0.88
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics (2006) 0.88
Activation by interferon-gamma of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas. Clin Mol Pathol (1995) 0.88
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer (2009) 0.88
HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol (1997) 0.86
Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer (2014) 0.85
Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics (2004) 0.85
Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol (2011) 0.84
Lymphocyte infiltration in oesophageal carcinoma: lack of correlation with MHC antigens, ICAM-1, and tumour stage and grade. J Clin Pathol (1996) 0.84
HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression. Br J Cancer (1996) 0.84
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. Int J Mol Sci (2015) 0.84
Identification of an alternate splice form of tapasin in human melanoma. Hum Immunol (2010) 0.83
Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer (1995) 0.83
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch (2003) 0.83
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res (2003) 0.83
Transcriptional regulation of the MHC class I HLA-A11 promoter by the zinc finger protein ZFX. Nucleic Acids Res (1996) 0.82
A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. Mol Cell Proteomics (2013) 0.81
Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol (2003) 0.81
HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology (2002) 0.81
Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest (1995) 0.81
Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer (1999) 0.80
NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett (2015) 0.79
Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus. J Clin Pathol (2006) 0.79
Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br J Cancer (2000) 0.79
Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses. Br J Cancer (2011) 0.79
A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1. Br J Cancer (2000) 0.79
Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol (2013) 0.79
Bone specific immunity and its impact on metastasis. Bonekey Rep (2015) 0.78
Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes. Br J Cancer (2000) 0.77
Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med (2011) 0.77
Targetless T cells in cancer immunotherapy. J Immunother Cancer (2016) 0.77
Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy. Proc Natl Acad Sci U S A (2014) 0.76
Different N-terminal isoforms of Oct-1 control expression of distinct sets of genes and their high levels in Namalwa Burkitt's lymphoma cells affect a wide range of cellular processes. Nucleic Acids Res (2016) 0.76
Gene expression profile analyses of mice livers injured by Leigongteng. World J Gastroenterol (2007) 0.75
False homozygosity results in HLA genotyping due to loss of chromosome 6 in a patient with acute lymphoblastic leukemia. Korean J Lab Med (2011) 0.75
Human papillomavirus, high-grade intraepithelial neoplasia and killer immunoglogulin-like receptors: a Western Australian cohort study. Infect Agent Cancer (2013) 0.75
The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol (2016) 0.75
Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology (2015) 0.75
MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer (1996) 0.75
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today (1997) 2.89
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer (2001) 2.07
Monoclonal antibodies as probes for differentiation and tumor-associated antigens: a Forssman specificity on teratocarcinoma stem cells. Cell (1978) 1.97
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer (1990) 1.56
Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer (1992) 1.47
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer (1988) 1.46
Loss of MHC class-I expression in cervical carcinomas. Int J Cancer (1990) 1.40
Capping of exogenous Forssman glycolipid on cells. J Cell Biol (1979) 1.35
Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology (2007) 1.34
The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem (2000) 1.33
Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis (2001) 1.33
Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med (2001) 1.31
Expression of a Forssman antigenic specificity in the preimplantation mouse embryo. Cell (1978) 1.28
Theta alloantigen on mouse and rat fibroblasts. Nat New Biol (1973) 1.28
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Characterization of the human trophoblast-leukocyte antigenic molecules defined by a monoclonal antibody. J Immunol (1986) 1.19
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer (1994) 1.19
The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer (1992) 1.19
New cell surface antigens in rat defined by tumors of the nervous system. Proc Natl Acad Sci U S A (1975) 1.15
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer (1993) 1.13
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer (1995) 1.13
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens (2003) 1.09
Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. EMBO J (1995) 1.08
HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer (1989) 1.08
The HLA crossroad in tumor immunology. Hum Immunol (2000) 1.06
HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer (1998) 1.06
Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer (1990) 1.06
HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res (1992) 1.05
HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis (1990) 1.04
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer (2005) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer (1994) 1.03
Morbidity of trisomy 18 includes delivery by caesarean section. Lancet (1980) 1.03
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer (1996) 1.02
TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol (2004) 1.01
Comparison of oral health among older people with and without dementia. Community Dent Health (2014) 1.01
Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer (1989) 1.01
Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer (1999) 1.00
Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother (1994) 1.00
Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother (1998) 0.99
Identity tests: determination of cell line cross-contamination. Cytotechnology (2006) 0.99
Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol (1991) 0.99
A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer (2006) 0.99
Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem (1994) 0.97
A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol (2009) 0.97
Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology (1995) 0.97
Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br J Cancer (1990) 0.96
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother (2001) 0.96
Effect of mitomycin-C on human foreskin fibroblasts used as feeders in human embryonic stem cells: immunocytochemistry MIB1 score and DNA ploidy and apoptosis evaluated by flow cytometry. Cell Biol Int (2006) 0.96
Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Cancer Res (1997) 0.96
MHC expression on human tumors--its relevance for local tumor growth and metastasis. Semin Cancer Biol (1991) 0.96
5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol (1998) 0.96
Biological implications of HLA-DR expression in tumours. Scand J Immunol (1995) 0.96
Separation distress call in the human neonate in the absence of maternal body contact. Acta Paediatr (1995) 0.95
Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer (1996) 0.95
Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens (1998) 0.95
Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Aliment Pharmacol Ther (2001) 0.94
Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol (1999) 0.94
Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr (2003) 0.93
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer (2001) 0.93
Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 0.93
Expression of HLA G in human tumors is not a frequent event. Int J Cancer (1999) 0.93
Cloned human teratoma cells differentiate into neuron-like cells and other cell types in retinoic acid. J Cell Sci (1984) 0.93
Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother (1994) 0.93
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res (1997) 0.92
Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol (2009) 0.91
Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens (1996) 0.91
Tracking genetically engineered bacteria: monoclonal antibodies against surface determinants of the soil bacterium Pseudomonas putida 2440. J Bacteriol (1992) 0.91
Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. J Cell Sci (1995) 0.90
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer (2007) 0.90
Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol (2007) 0.90
Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl (1991) 0.90
Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol (2000) 0.90
Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J Pathol (1998) 0.89
Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet (1987) 0.89
Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer (2003) 0.89
Presence of HPV 16 sequences in laryngeal carcinomas. Int J Cancer (1990) 0.89
HLA antigens and cervical carcinoma. Nature (1992) 0.89